PetMed Express Reports 19.9% Decline in Net Sales and $6.1 Million Loss in Q1 Fiscal 2027

PetMed Express, Inc. reported a significant decline in financial performance for the first quarter of fiscal 2027, ending June 30, 2026. The company recorded net sales of $41.0 million, a decrease of approximately 19.9% from $51.2 million in the same period last year. This decline was primarily attributed to a drop in prescription medication sales, which was slightly offset by lower consumer promotional usage. The company also experienced a decrease in both reorder sales and new order sales, with reorder sales falling to $32.8 million and new order sales to $6.6 million, reflecting a year-over-year decline of 20.5% and 20.2%, respectively.

In terms of profitability, PetMed Express reported a net loss of $6.1 million, or $(0.28) per share, compared to a net loss of $34.2 million, or $(1.65) per share, in the prior year. The loss from operations improved to $(6.2) million from $(34.1) million, largely due to a significant reduction in total operating expenses, which decreased from $48.5 million to $17.6 million. This reduction was driven by the absence of a prior-year impairment charge of $27.3 million and lower general and administrative expenses, which fell by 13.5% to $11.2 million.

Operationally, the company reported acquiring approximately 70,000 new customers during the quarter, down from 85,000 in the same period last year. The average order value increased slightly to $101 from $99. The company’s recurring net sales, which include AutoShip & Save subscriptions and membership-related revenue, represented 61.5% of total gross sales, up from 57.6% a year ago. However, the company’s cash and cash equivalents decreased to $13.1 million from $21.4 million at the end of the previous fiscal year, raising concerns about liquidity.

In response to ongoing challenges, including increased competition and macroeconomic pressures, management has implemented a strategic plan focused on optimizing advertising and media spending, reducing operating expenses, and limiting capital expenditures. The company has also entered into a purchase and sale agreement to sell its properties in Delray Beach, Florida, for $37.0 million, which is expected to close in the third quarter of fiscal 2027. This transaction is part of a broader effort to enhance liquidity and operational efficiency.

Looking ahead, PetMed Express acknowledges the potential for continued revenue challenges due to changing consumer behavior and competitive pricing pressures. While management believes that their strategic initiatives will mitigate some of these risks, they caution that future sales growth remains uncertain. The company’s ability to navigate these challenges will be critical as it seeks to stabilize its financial position and improve profitability in the coming quarters.